Arnold Caplan(founder of Osiris), now CEO of Biotime's OrthoCyte. He gave a pre-clinical update of Renevia last year, check out BTX video page for the presentation.
Biotime solates and the original cells that form the lower limb. These hESC's are cross checked with gene expression to prove they are the 'gold standard'. Dr. West compares these gene markers as the 'zip code' of embryonic formation. Extensive patent portfolio of these include various hESC progenitor cartilage and bone cells of the leg, arm, jaw, knee & elbow, nose, and sternum.
This video update marks the start of Biotimes cartilage regeneration therapeutics which is the most extensive, thorough cartilage regen IP in the world. This is clearly Biotimes main focus and will likely be their biggest money maker over the next decade if all goes well.
On a side note, last year, the Oakland Raiders football team practices across the way from Biotimes headquarters has shown interest in their technology. Sports will likely be one of the first areas of application for this stuff, the regeneration a players knee cartilage and or bone will of course pay top dollar.
Biotime is ahead of the curve! Companies that use our IP for their therapies will pay us a %. Same deal with UCLA recent announcement to use our ECM hydrogel for stroke.
They key thing to remember here is timing. The overall timing of Biotimes products are very good. Don't want to be one of these companies who patents early tech and then puts all there eggs in one product just to get dated within months.
This industry is fast moving and so Dr. West is slowly cornering, genetic ip and cancer marker IP along with the rest of the stem cell IP. So that as the technology ripens Biotime will be right there at the forefront.
Good start to a slow and steady climb over the next year.....Bashers better stop bashing and just get on the train. TOOT TOOT!!!
Cornell's hospital here in NYC is rated #5 in the country in the cardio dept. The fact that they as well as UCLA want to work with Biotime tell you something.
Another one of biotimes 'picks & Shovels" being picked up by regen gold diggers!
Interesting article, hdrogel technology maturing. Google post title for article from ScienceDigest.
"This is an important step forward in our commercialization efforts and brings us closer to delivering this much-needed matrix technology for the emerging field of regenerative medicine," stated William P. Tew , PhD, Chief Commercialization Officer of BioTime, Inc. "The technology forms a foundation for the delivery of cell-based therapeutic products in both the adult and embryonic stem cell marketplace. Current preclinical studies at leading medical institutions have shown that HyStem® hydrogels are compatible with a wide variety of tissue types including brain, bone, skin, nerve, cartilage, and heart."
In the clinical application described in this CIP, ReneviaTM will be used as a delivery matrix for autologous adipose cells in order to restore subcutaneous tissue lost as a result of injury, oncologic resection, or congenital defects. Restoration of the normal skin contour is an important quality-of-life issue, not only in elective cosmetic procedures, but also in reconstructive surgeries needed to repair deformities and traumatic injuries to the face and upper extremities. BioTime's plan is to bring ReneviaTM to the medical market first in the European Union , where the regulatory pathway will allow for faster approval. Once the use of ReneviaTM is established in Europe , BioTime plans to address an even larger potential market in the United States
I don't think any of Biotimes subsidiaries are no way near there potential worth.
West did hint at a near term major corporate partnership so i wouldn't worry too much!
Not raking in the bucks as expected at this point. Amazing that we have 5MIL in cash considering we expanded so much in the last year. Acquired Geron assets as well as LifeMap, hired new employees, etc.
I do believe BTX is at a major turning point as a company, making a transition from an R&D to therapeutics company. Most pieces are in place, but money is the question at this point in terms of funding clinical trials.
Dr. West is just as good a business man as he is scientist so i have no doubt he will sure up funding.
I would think Dr. West would announce a partnership soon to get the stock back in the $4-6 range, or at least a strong indication os success in pre-clinical studies.
On the therapeutics front:
-Weill Cornell Medical and OncoCyte announced a commencement on anti-tumor animal/preclinical studies.
-Arnold Caplan CEO of OrthoCyte will be speaking in numerous places in the next few months(April22, June 23, and August 19), which may indicate announcement concerning OrthoCytes cartilage regen progress.
Over all i think investors spot a buying opportunity right now before the 'gettin gets good' this year. To end i would just say now might not be a good time to bet against West. Again, he is a great biz man and very aggressive when his back is against the wall. So i would not be surprised if he counteracted 4Q results with some ground breaking news in the short term.
Thats it for now!
About Dr. Jin
Dr. David Jin became the Chief Medical Office for BioTime Inc. as well as its two subsidiaries, namely BioTime Asia Limited and OncoCyte Corporation since 2010. Dr. Jin is a licensed physician in the U.S. who has over 15 years of diverse experience in clinical trials, strategic consulting, regulatory affairs, and biotechnology development. After graduating as class valedictorian with summa cum laude distinction from Massachusetts College of Pharmacy in 1992, Dr. Jin further obtained a combined M.D. and Ph.D. degrees from the State University of New York Downstate College of Medicine. He completed his clinical training in internal medicine, hematology, and oncology at New York-Presbyterian Hospital (the teaching hospital for Columbia and Cornell University School of Medicine), and subsequently became clinical and research faculty at Cornell. During his academic tenure, Dr. Jin has directed over 10 clinical trials at various R&D stages sponsored by major pharmaceutical companies. He has served as senior clinician-scientist at the Ansary Stem Cell Institute and published over 30 peer-reviewed research and clinical papers, some in prestigious journals including Nature, Nature Medicine, Cell, and PNAS. Dr. Jin has worked for the U.S. Food and Drug Administration as medical reviewer for oncology product development. Recently, Dr. Jin has been appointed by China’s Ministry of Health as external adviser and member of the evaluation committee for MOH’s Third Category Medical Treatment Technology (for regulation and standardization of stem cell therapy and cell-based immunotherapy), as well as adviser to the Chinese-UK “Dynasty Project” to establish an international collaborative zone for clinical medicine in Wuhan BioLake.
ExecRank Honors David Jin, M.D., Ph.D. of BioTime Inc. as a Top Chief Medical Officer for 2012
SAN FRANCISCO --
David Jin, M.D., Ph.D., Chief Medical Officer, at BioTime Inc. (NYSE/AMEX: BTX) has been selected by ExecRank as a “Top Chief Medical Officer” for 2012. The rankings are the result of 2-years of research and feedback from evaluation committees and top Chief Medical Officers that yielded an algorithm for how to rank Medical Executives based on their performance in 24 key areas.
According to Adam Navrozally, Lead Analyst for the rankings division of ExecRank, “Dr. Jin has a long record of success in strategic research and development, while complying with increasingly strict regulatory standards. His strong record of success in both academic presentations and research publications makes him a strong asset to BioTime. He is highly regarded in his field, and amongst other Chief Medical Officers.”
According to Dr. Jin, “It is truly an honor to be elected by my peers, and recognized by ExecRank, as a Top Chief Medical Officer for 2012. I share this achievement with my colleagues at BioTime and our subsidiaries who support me and the corporation. The award has motivated me to continue to work toward achieving the best practices in the field of stem cell and regenerative medicine.”